FN-1501

Generic Name
FN-1501
Brand Names
Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
Drug Type
Small Molecule
Chemical Formula
C22H25N9O
CAS Number
1429515-59-2
Unique Ingredient Identifier
6MC966B505
Background

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication

Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions
Transplanted Organ Rejection
Associated Therapies
-
Clinical Trials
Related News

Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2004-03-25
Last Posted Date
2010-04-02
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00008151
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

First Posted Date
2004-03-09
Last Posted Date
2020-01-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
37
Registration Number
NCT00078858
Locations
🇺🇸

Stanford University Hospitals and Clinics, Stanford, California, United States

🇺🇸

Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States

🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 7 locations

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

First Posted Date
2004-03-08
Last Posted Date
2019-11-04
Lead Sponsor
University of Maryland, Baltimore
Registration Number
NCT00006350
Locations
🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

First Posted Date
2004-02-20
Last Posted Date
2014-05-02
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
20
Registration Number
NCT00003572
Locations
🇺🇸

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2004-01-12
Last Posted Date
2017-05-15
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
87
Registration Number
NCT00075478
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

🇩🇪

Medizinische Univ Klinik Koln, Koln, Germany

and more 7 locations

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

First Posted Date
2003-12-12
Last Posted Date
2019-11-13
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
79
Registration Number
NCT00008177
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

First Posted Date
2003-07-14
Last Posted Date
2013-12-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
668
Registration Number
NCT00064701

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

First Posted Date
2003-05-07
Last Posted Date
2017-12-08
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
21
Registration Number
NCT00060424
Locations
🇺🇸

Veterans Administration Center-Seattle, Seattle, Washington, United States

🇮🇹

University of Torino, Torino, Italy

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

First Posted Date
2003-02-06
Last Posted Date
2017-10-16
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
16
Registration Number
NCT00054353
Locations
🇮🇹

University of Torino, Torino, Italy

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

First Posted Date
2003-02-06
Last Posted Date
2020-02-10
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
41
Registration Number
NCT00053989
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy